Sun Pharma falls on anti-diabetes drug recall

Shares in Sun Pharmaceutical Industries Ltd fall as much as 2.8 percent after the US Food and Drug Administration said the drug maker was voluntarily recalling 2,528 bottles of its generic version of diabetes drug Glumetza from US-based Santarus Inc.

Sun began recalling the bottles of metformin HCL extended-release tables in the United States on January 28, 2014, after it received a customer complaint that one of the bottles contained tablets of epilepsy drug Gabapentin, the FDA said in a release on its web site.

A Sun spokeswoman confirmed the recall on Monday morning, adding that the company did not expect a significant impact.

The FDA classified the recall as a "Class II," which signifies a remote chance of severe adverse consequences or death due to the product flaw.

The Sun recall comes as shares in Ranbaxy Laboratories Ltd fell as much as 3.8 percent on Monday after the drug maker recalled more than 64,000 bottles of the generic version of a cholesterol-lowering drug in the United States after a doseage mix-up was detected.


  • Despite challenges, India’s target of 33-35% reduction of carbon emission can be achieved

    There are responsibilities which go with being a global power and there is no issue bigger than environment where a country has to demonstrate it mean


Stay informed on our latest news!


Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs


Tushar Gandhi

Will Digital India feed the starving?

For the past few days, Digital India has become as ...

Purnendu Ghosh

Spending time in a fictional world

Our world consists of both fiction and non-fiction. Our reaction ...

Shona Adhikari

Tapestries have become the talk of the town

Bringing various forms of art together in festivals, is what ...


William D. Green

Chairman & CEO, Accenture